GT BIOPHARMA, INC. Payments to Acquire Investments
GT BIOPHARMA, INC. (GTBP) reported Payments to Acquire Investments of $6.99 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2023-05-15
- GT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2023-03-31 was $6.99M.
- GT BIOPHARMA, INC. payments to acquire investments for the quarter ending 2021-12-31 was -$2.99M.
- GT BIOPHARMA, INC. payments to acquire investments for fiscal 2021 was $23.04M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|
| 2023-03-31 | $6.99M 10-Q · filed 2023-05-15 | ||
| 2021-12-31 | -$2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $23.04M 10-K · filed 2022-03-28 | |
| 2021-09-30 | $26.03M 10-Q · filed 2021-11-10 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |